Highlights  Intracisternal orexin-A improves intestinel hyperpermeability in rats  Atropine or vagotomy blocks the action of barrier function by orexin-A  Orexin receptor antagonist blocks the improvement of barrier function J o u r n a l P r e -p r o o f 2  Brain orexin controls intestinal barrier function via the vagal cholinergic pathway Abstract Orexins are neuropeptides that are implicated in a number of functions. With regard to the gastrointestinal functions, orexin acts centrally to regulate gastric secretion, gastrointestinal motility and visceral sensation. Little is however known about a role of central orexin in the control of intestinal barrier function. The present study was performed to clarify whether brain orexin plays a role in the control of intestinal permeability. Colonic permeability was estimated in vivo by quantifying the absorbed Evans blue in colonic tissue in rats. Intracisternally administered orexin-A but not orexin-B dose-dependently blocked the increased intestinal permeability by lipopolysaccharide (LPS) or corticotropin-releasing factor while intraperitoneally injected orexin-A failed to block it. Atropine or vagotomy abolished the action by central orexin-A. Intravenous injection of 2-deoxy-D-glucose (2-DG), a central vagal stimulant, significantly blocked the LPS-induced increase in intestinal permeability and atropine prevented the action of 2-DG. Intracisternal injection of SB-334687, a selective orexin 1 receptor antagonist, significantly blocked the action of 2-DG-induced improvement of intestinal hyperpermeability. These results suggest that exogenously administered or endogenously released orexin acts centrally to improve the intestinal hyperpermeability by LPS via the vagal cholinergic pathway. The findings also suggest for the first time that the brain could control intestinal permeability. The
Introduction
The intestinal barrier is one of the largest interfaces between the outer world and the human internal milieu. The ability to protect from harmful luminal content and to control the mucosal permeability is defined as intestinal barrier function. A disturbed intestinal barrier function has been described in many human diseases such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) [1] . Several other non-gastrointestinal (GI) diseases have been associated with leaky gut. These include asthma, autism, Parkinson's disease, multiple sclerosis, eczema, psoriasis, eosinophilic esophagitis, depression, chronic fatigue syndrome, multiorgan failure syndrome, non-alcoholic fatty liver disease, alcoholic cirrhosis, obesity, metabolic syndrome, pancreatitis and rheumatoid arthritis [1] . Thus, improvement of disturbed intestinal barrier function may contribute to control of activity of several GI and non-GI diseases.
Intestinal barrier function is regulated by a number of factors such as tight junction proteins in the epithelium, peripheral neuroimmune-related molecules and microbiota [1, 2] . Little is known however how the brain controls intestinal permeability.
J o u r n a l P r e -p r o o f
Orexins are neuropeptides that are localized in neurons in the lateral hypothalamus [3, 4] . Despite their highly restricted origin, orexin nerve fibers are identified widely throughout the central nervous system (CNS) [5] and orexins are implicated in a number of functions. These include feeding, sleep/awake, anxiety/depression or energy balance [6] . In addition, orexin acts centrally to regulate gastrointestinal functions such as gastric secretion, gastrointestinal motility and visceral sensation [7] [8] [9] [10] [11] . We do not know however at this moment whether orexin is involved in the regulation of intestinal barrier function. The present study was therefore performed to clarify a hypothesis that brain orexin may play a role in the control of intestinal permeability in rats. Here we provide an evidence that brain orexin improves colonic hyperpermeability through the vagal cholinergic pathway, suggesting for the first time intestinal barrier function is regulated by the CNS.
Methods

Ethical considerations
Approval was obtained from the Research and Development and Animal Care committees at Asahikawa Medical University (No. 13030) for all of the experiments conducted in this study.
Animals
Male Sprague-Dawley rats (Charles River Laboratory, Atsugi, Japan) weighing about 200 g were housed under controlled light/dark conditions (lights on: 07:00-19:00), and the room temperature was regulated at 23-25C. Rats were allowed free access to standard rat chow (solid rat chow; Oriental Yeast Co., Tokyo, Japan) and J o u r n a l P r e -p r o o f tap water. All of the experiments were performed using conscious animals, which had been deprived of food for 24 h but with free access to water until the initiation of the experiments.
Chemicals
Synthetic human orexin-A, orexin-B and rat/human corticotropin-releasing factor (CRF) were purchased from Peptide Institute Inc., Osaka, Japan and dissolved in 
Measuring colonic permeability
The permeability was determined 3 h or 4 h after injecting LPS or CRF, respectively according to our previous reports [12, 13] . Colonic permeability measurement was performed as previously described [12] . The rats anesthetized by intraperitoneal administration of the mixture of medetomidine hydrochloride (Orion Pharma Ltd., Dhaka, Bangladesh, 0.15 mg/kg), midazolam (Sandoz, Tokyo, Japan, (3-Fr, Atom, Tokyo, Japan) was inserted into the proximal colon through the hole and fixed by purse-string sutures. The colon was gently flushed with phosphate buffered saline (PBS, 37 °C) using the catheter until all stools were washed out. Generally, the required volume of PBS was approximately 10 ml and the perfusion rate was 5 ml/min.
Then another ligation was added on the colon at approximately 4 cm from the proximal ligation, and 1 ml of 1.5% Evans blue in PBS was instilled into the colon segment between ligations through the catheter. Fifteen min later, the animals were killed and the colons were excised. Later they were washed with PBS and 1 ml of 6 mM N-acetyl-cysteine, and were opened and placed in 2 ml of N, N-dimethylformamide for 12 h. The permeability was calculated by measuring the Evans blue concentration in the supernatant using a spectrophotometer at 610 nm.
Experimental procedures
Initially, we examined the dose-dependent effects of intracisternal injection of orexin-A on the subcutaneous LPS-induced colonic hyperpermeability. Rats received intracisternal or intraperitoneal injections of several doses of orexin-A or orexin-B, and then LPS or CRF was injected. Intracisternal injection was performed under brief isoflurane anesthesia using a 10-μl Hamilton microsyringe after the rats were mounted in a stereotaxic apparatus (David Kopf Instruments, Tijunga, CA), as reported previously [14] . Next, to clarify whether the vagal system is involved in the central orexin-induced changes of LPS-evoked intestinal hyperpermeability, we examined the effect of the intraperitoneal injection of atropine (1 mg/kg) or surgical vagotomy on the intracisternally administered orexin (10 μg/10 μl)-induced change of colonic hyperpermeability by LPS. The surgical bilateral vagotomy was performed as J o u r n a l P r e -p r o o f previously described [7] . To examine whether endogenous orexin in the brain mediates the brain orexin-induced alternation of colonic hyperpermeability, we tested the effect of intracisternal SB-334867 (40 μg), a selective OX1R antagonist. The dose of LPS, CRF, atropine, 2-DG or SB-334867 was selected according to our previous publications [10] [11] [12] [13] .
Statistical analysis
The data were expressed as means ± standard error (SE). The data were compared with Student's t-test or one-way analysis of variance followed by Tukey's Multiple Comparison Test. P < 0.05 was considered statistically significant.
Results
We first examined the effects of central orexin on the intestinal permeability.
As shown in Figure 1A , subcutaneously administered LPS at a dose of 1 mg/kg significantly increased the colonic permeability, being in good agreement with our previous study [12] . Intracisternal injection of orexin-A at a dose of 10 μg by itself did not change the basal colonic permeability (27.2 ± 1.6 in saline vs 28.1 ± 0.9 in orexin-A, μg/g tissue) but significantly inhibited the LPS-induced colonic hyperpermeability. On the other hand, intraperitoneally administered orexin-A or intracisternal injection of orexin-B at a dose of 10 μg failed to change the colonic permeability ( Table 1 ), suggesting that orexin-A specifically acts centrally to improve the colonic hyperpermeability. Intraperitoneal injection of CRF at a dose of 50 μg/kg significantly increased the colonic permeability, as shown in our previous study [13] . In this condition, intracisternal injection of orexin-A at the similar doses could potently block J o u r n a l P r e -p r o o f the colonic hyperpermeability ( Figure 1B) , confirming the improvement of intestinal barrier function by brain orexin in an another model.
Next, we examined the mechanisms of orexin-A-induced improvement of colonic hyperpermeability. Orexin acts centrally in the dorsal motor nucleus of the vagus (DMN) to increase the vagal tone [15, 16] and the proximal colon evaluated in this study is innervated by the vagus nerve. We therefore examined the role of the vagal system in the improvement of intestinal barrier function by brain orexin. Although 
Discussion
With regard to the role of central orexin in digestive functions, we have previously showed that orexin act centrally to stimulate gastric secretion or gastrointestinal motility, and induce a visceral atininociceptive action [7] [8] [9] [10] [11] . In addition, the present study has shown that exogenously administered or endogenously released orexin improves the intestinal hyperpermeability, suggesting that orexin also [23] . A couple of studies [15, 16] have shown that orexin-A directly activates the DMN neurons and OX1R was highly expressed in the DMN neurons [24] . These findings suggest that orexin-A directly acts the OX1R and excites the DMN neurons that project to the proximal colon evaluated in the present study.
Based upon these results, we could conclude that central injection of orexin-A activates directly the DMN neurons, followed by increasing the vagal tone, thereby improving intestinal permeability as shown in this study.
Next, we tried to clarify whether endogenous orexin in the brain play a role in the control of intestinal permeability. As shown in this study, we have demonstrated with the magnitude of altered colon epithelial permeability, suggesting a tight correlation between visceral sensation and intestinal permeability. We have previously showed that orexin induced a visceral hyposensitivity in rats [11] and the present study clearly demonstrated that orexin improved the intestinal permeability. These findings suggest that the improvement of intestinal barrier function by orexin would be deeply associated with the changed visceral sensation. In other words, orexin may act centrally to improve intestinal permeability, followed by inducing a visceral antinociception.
We have recently presented the hypothesis that decreased central orexin signaling may be involved in the development of IBS [11, 24, 28] . This is because decreased orexin signaling has been shown to induce a number of characteristics observed in patients with IBS, including disturbances in gastrointestinal motility, visceral hypersensitivity, depressive symptoms, appetite loss, and disordered sleep [19. 29]. The improvement in increased intestinal permeability by orexin demonstrated in this study further supports the above hypothesis since intestinal hyperpermeability is also an important pathogenic feature of IBS [1, 19] .
In conclusion, brain orexin plays a vital role the regulation of intestinal barrier function, and the orexin signal is considered to be a target to control the altered intestinal barrier function especially in IBS.
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